Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-02T19:09:31.006Z Has data issue: false hasContentIssue false
  • English
  • Français

The Murine Ependymoblastoma: Growth Pattern and Survival in C57B1/6J Mice

Published online by Cambridge University Press:  18 September 2015

Paul J. Muller ,
Kyu H. Shin  and
Doo H. Shin
Paul J. Muller
Affiliation:
Tom Baker Cancer Centre and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta
Kyu H. Shin*
Affiliation:
Tom Baker Cancer Centre and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta
Doo H. Shin
Affiliation:
Tom Baker Cancer Centre and the Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta
*
1331-29 Street N.W., Calgary, Alberta, Canada, T2N 4N2.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The murine ependymoblastoma is a transplantable tumor of cerebral origin. The growth pattern and survival times of the murine ependymoblastoma implanted peripherally and intracranially in non nude C57B1/6J mice have been found to be predictable and consistent when examined by means of Tumor Cell Dose Assessment (end point solution), Tumor Growth and Survival Assessment. The results suggest that a greater tumor cell dose is required to generate peripheral tumor take than brain tumor take. This difference may result from a greater immunologic response to tumor implanted peripherally than into the immunologically privileged brain.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 10 , Issue 2 , May 1983 , pp. 105 - 109
Copyright
Copyright © Canadian Neurological Sciences Federation 1983

References

Ausman, J.I., Shapiro, W.R., Rail, D.P. (1970). Studies on the chemotherapy of experimental brain tumors: Development of an experimental model. Cancer Res. 30:2394–2400.Google ScholarPubMed
Bullard, D.E., Bigner, D.D., (1980). Animal models and virus induction of tumors. In, Brain Tumors. Scientific Basis, Clinical Investigation and Current Therapy. Ed. Thomas, E.D. and Graham, D.I.; Butterworth Inc. pp. 70–76.Google Scholar
Chirigos, M.A., Humphreys, S.R., Goldin, A. (1962). Effectiveness of Cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L1210. Cancer Res. 22:187–195.Google ScholarPubMed
Crafts, D., Wilson, C.B. (1977). Animal models of brain tumors. In. Modern Concepts in Brain Tumor Therapy. Laboratory and Clinical Investigations. N.C.I. Monogr. 46, pp. 11–17.Google Scholar
Geran, R., Congleton, G.F., Dudeck, L.E., Vendetti, J., Abbott, B.J., Gargus, J.L. (1974). A mouse ependymoblastoma as an experimental model for screening potential antineoplastic drugs. Cancer Chemothr. Rep. 4:53–87.Google ScholarPubMed
Levin, V.A., Shapiro, W.R., Clancy, T.P., Oliverio, V.T. (1970). The uptake, distribution, and antitumor activity of 1 – (2-chloroethyl) – 3-cyclohexyl – 1-nitrosourea in the murine glioma. Cancer Res. 30:2451–2455.Google ScholarPubMed
Levin, V.A., Freeman-Dove, M.A., Maroten, C.E. (1970). Dihydrogalactitol (NSC-13213): pharmacokinetics in normal and tumor bearing rat brain and antitumor activity against three intracerebral rodent tumors. J. Natl. Cancer Inst. 56:535.CrossRefGoogle Scholar
Muller, P.J., Shin, K.H. (1982). Superfractionated radiotherapy in C57B1/6J mice. Canad. J. Neurol. Sci. 9:295.Google Scholar
Muller, P.J., Tator, C.H. (1978). The effect of amphotericin B on the survival of brain tumor bearing mice treated with CCNU. J. Neurosurg. 49:579–588.Google ScholarPubMed
Muller, P.J., Tator, C.H. (1980). Bloom, M.The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model. J. Neurosurg. 52:359–366.CrossRefGoogle Scholar
Schwartz, M.L., Tator, C.H., Hoffman, H.J. (1972). The uptake of hydrocortisone in mouse brain and ependymoblastoma. J. Neurosurg. 36:178–183.CrossRefGoogle ScholarPubMed
Seligman, A.M., Shear, M.J. (1939). Studies in carcinogenesis. VIII. Experimental production of brain tumors in mice with methylcholanthrene. Am. J. Cancer, 37:364.Google Scholar
Shapiro, W.R. (1971). Studies on the chemotherapy of experimental brain tumors. Evaluation of 1 – (2-chlorohexyl) – 3-cyclohexyl – 1-nitrosourea, vincristines, and 5-fluorouracil. J. Natl. Cancer Inst. 46:359–368.Google Scholar
Shapiro, W.R., Ausman, J.I., Rail, D.P. (1970). Studies on the chemotherapy of experimental brain tumors: Evaluation of 1,3 – bis(2 – chloroethyl) – 1-nitrosourea, cyclophosphamide, mithramycin. and methotrexate. Cancer Res. 30:2401–2413.Google Scholar
Tator, C.H. (1972). Chemotherapy of brain tumors. Uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastoma in mice. J. Neurosurg. 37:1–8.Google ScholarPubMed
Walker, M.D. (1977). Brain tumor study group: A survey of current activities. In: Modern Concepts of Brain Tumor Therapy: Laboratory and Clinical Investigations. Natl. Cancer Inst. Mongr. #46:209–212.Google Scholar
Wassenaar, W., Tator, C.H. (1976). Carbohydrates as potential diagnostic tracers for brain tumors. J. Neurosurg. 44:668–676.CrossRefGoogle ScholarPubMed
Wassenaar, W., Tator, C.H., So, W.S. (1973). The development of an intracerebral glioma model for brain tumor chemotherapy. J. Neurosurgy. 39:293–301.CrossRefGoogle ScholarPubMed
Zimmerman, H.M., Arnold, H. (1941). Experimental brain tumors. I. Tumors produced by methylcholanthrene. Cancer Res. 1:919–938.Google Scholar